Nido Biosciences
Watertown, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $109M
Overview
A preclinical biotech targeting ion channels and purinergic receptors to develop small molecule therapies for neuroinflammatory diseases.
NeuroscienceImmunology
Technology Platform
A precision neuroimmunology platform focused on structure-based design of small molecules targeting specific ion channels and purinergic receptors to modulate neuroinflammatory pathways.
Funding History
1Total raised:$109M
Series A$109M
Opportunities
Successfully drugging its novel neuroimmune targets could open new treatment paradigms for a range of severe neurological and autoimmune conditions with limited options.
Risk Factors
High preclinical biological risk associated with novel, unvalidated targets in the complex neuroimmune axis, with potential for unforeseen safety issues.
Competitive Landscape
Faces competition from both neurology and immunology-focused companies, but its specific focus on small molecule neuroimmune modulators is a specialized niche.